Subcutaneous implantable bladder drug delivery device

Abstract

The utility model discloses a subcutaneous implantable bladder drug delivery device which comprises a drug storage part and a catheter part, the drug storage part and the catheter part are both implanted in subcutaneous tissue, the interior of the drug storage part is communicated with one end of the catheter part, and the other end of the catheter part extends into bladder tissue; the medicine storage part comprises a base and a silicon capsule, the base is arranged in a shell shape with the top end open, the silicon capsule is of a silica gel top cover structure with the middle protruding upwards, and the edge of the bottom end of the silicon capsule is connected with the edge of the base in a sealed mode and combined with the base to form a sealed cavity for containing medicine liquid; and one side of the base is provided with a conduit joint communicated with the interior of the sealed cavity and is communicated with the conduit piece through the conduit joint. According to the utility model, the administration mode of bladder perfusion chemotherapy is changed, the catheter does not need to be inserted frequently for many times, and the catheter can be used for a long time only by one-time implantation, is low in cost, economical and practical, and is beneficial to reducing the economic burden of a patient.

Description

Technical Field

[0001] The utility model relates to the medical field, in particular to a subcutaneous implantable bladder medication device. Background Art

[0002] Bladder cancer is one of the three major tumors of the urinary system and the sixth most common malignant tumor in my country, with men being the most susceptible group. The core of the treatment of early bladder cancer (stage I) is surgical removal of the tumor, preservation of the bladder, and regular intravesical chemotherapy after surgery. Intravesical chemotherapy is the main treatment for patients with early bladder cancer, with an average of 18 to 20 times a year (once a week in the early stages, once every 4 weeks after 8 times, with a total cycle of 1 to 2 years).

[0003] The basic operating steps of existing bladder instillation chemotherapy are: 1. Disinfect and lay the towel; 2. Insert the catheter through the urethra; 3. Inject chemotherapy drugs from the catheter; 4. Remove the catheter; 5. The patient will excrete the drugs by himself after 30 to 60 minutes; for example, a bladder cancer chemotherapy drug injector disclosed in patent number CN202011484574.2 adopts this method;

[0004] However, the disadvantages of transurethral administration are as follows:

[0005] 1. Frequent insertion of urinary catheters can directly lead to urethral damage, resulting in serious complications such as urethral stenosis, dysuria, and urine retention;

[0006] 2. Multiple insertions of urinary catheters can easily lead to nosocomial urinary tract infection, causing clinical symptoms such as fever in patients;

[0007] 3. Insertion of a urinary catheter often fails in older men, especially those with prostatic hyperplasia, resulting in the inability to implement intravesical chemotherapy.

[0008] 4. The operation of the urinary catheter requires professionally trained medical personnel and has high technical requirements;

[0009] 5. Insertion of a urinary catheter usually causes urethral pain. In severe cases, it can lead to long-term urethral pain, burning discomfort, and eventually resistance to intravesical chemotherapy.

[0010] 6. Transurethral instillation of chemotherapy into the bladder is time-consuming, costly, and complex.

[0011] In summary, it is necessary to study a bladder drug delivery device with other drug delivery methods to solve the above problems. Summary of the invention

[0012] The utility model aims to solve the above problems and provide a subcutaneous implantable bladder medication device which has a simple structure and is convenient to use.

[0013] In order to achieve the above purpose, the technical solution of the utility model is:

[0014] A subcutaneously implantable bladder drug delivery device comprises a drug storage component and a catheter component, both of which are implanted in subcutaneous tissue, the interior of the drug storage component is connected to one end of the catheter component, and the other end of the catheter component extends into the bladder tissue; the drug storage component comprises a base and a silicon capsule, the base is in the shape of a shell with an open top, the silicon capsule is a silicone top cover structure with a raised middle portion, the bottom edge of the silicon capsule is sealedly connected to the edge of the base and combined with the base to form a sealed cavity for accommodating liquid medicine; a catheter joint connected to the interior of the sealed cavity is provided on one side of the base and is connected to the catheter component through the catheter joint.

[0015] Furthermore, an annular groove is integrally formed on the side wall of the base edge, and an annular protrusion adapted to the annular groove is integrally formed on the bottom edge of the silicone capsule; when the silicone capsule is connected to the base, the annular protrusion on the edge of the silicone capsule is embedded in the annular groove on the edge of the base and the annular protrusion is engaged and connected with the annular groove.

[0016] Furthermore, the bottom end surface of the base is a planar structure, and the bottom end surface of the base is circular, elliptical, or triangular, but not limited to circular, elliptical, or triangular.

[0017] Furthermore, the base is a metal base or a biomaterial base.

[0018] Furthermore, the maximum diameter of the base is less than 5 cm.

[0019] Furthermore, one end of the catheter member is provided with a positioning structure and is detachably connected to the catheter connector via the positioning structure, and the other end of the catheter member is inserted into the bladder tissue.

[0020] Furthermore, a plurality of side through holes are arranged on the peripheral side wall of one end of the catheter member inserted into the bladder tissue to increase the drug outlet area of ​​the catheter member.

[0021] Furthermore, one end of the catheter inserted into the bladder tissue is configured as a curved structure to prevent the end of the catheter from being separated from the bladder tissue.

[0022] Furthermore, the catheter member is a silicone catheter member.

[0023] Compared with the prior art, the utility model has the following advantages and positive effects:

[0024] Before use, the utility model firstly embeds the bladder drug delivery device in the subcutaneous tissue, and then inserts the catheter into the bladder tissue. Each time the bladder is instilled for chemotherapy, it is only necessary to use an ordinary syringe to inject the drug into the subcutaneous drug storage device through the skin and the silicon capsule, and the drug can enter the bladder through the catheter to achieve the purpose of bladder instillation chemotherapy; after the chemotherapy cycle is over, the bladder drug delivery device can be taken out from the subcutaneous tissue;

[0025] The utility model changes the administration method of bladder instillation chemotherapy, and no longer needs to insert the catheter frequently, and has the following beneficial effects:

[0026] 1. No need to administer the drug through the urethra, thus avoiding urethral injury, urinary tract infection and other conditions;

[0027] 2. It avoids the situation that the failure of catheter insertion affects the operation of chemotherapy, and is suitable for a wider range of people;

[0028] 3. Operators do not need professional training and can directly administer the drug subcutaneously. It is simple and convenient and can be completed by ordinary nursing staff;

[0029] 4. It avoids the pain caused by repeated insertion of the catheter, making the patient's bladder instillation chemotherapy more comfortable and easier to complete the chemotherapy cycle;

[0030] 5. The subcutaneous bladder drug delivery device only needs to be implanted once and can be used for a long time. It is low-cost and economical, which helps to reduce the financial burden of patients;

[0031] 6. The subcutaneous bladder drug delivery device is implanted superficially on the skin, making it easy to install and remove, and its safety performance is more reliable.

[0032] The present invention can replace or largely replace bladder instillation chemotherapy and the method of transurethral administration, and can benefit a large number of patients undergoing bladder cancer instillation chemotherapy, and is conducive to completing the chemotherapy cycle, controlling the progression of bladder cancer, and preventing its recurrence. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the embodiments of the utility model or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0034] Figure 1 It is a schematic diagram of the structure of the utility model;

[0035] Figure 2 It is a cross-sectional structural diagram of the medicine storage component. DETAILED DESCRIPTION

[0036] The following will be combined with the drawings in the embodiments of the utility model to clearly and completely describe the technical solutions in the embodiments of the utility model. Obviously, the described embodiments are only part of the embodiments of the utility model, not all of the embodiments. Based on the embodiments of the utility model, all other embodiments obtained by ordinary technicians in this field without creative work, any modifications, equivalent replacements, improvements, etc., should be included in the protection scope of the utility model.

[0037] like Figure 1 , Figure 2 As shown, this embodiment discloses a subcutaneous implantable bladder drug delivery device, including a drug storage member and a catheter member 3, both of which are implanted in subcutaneous tissue, the interior of the drug storage member is connected to one end of the catheter member 3, and the other end of the catheter member 3 extends into the bladder tissue;

[0038] The medicine storage device includes a base 1 and a silicon capsule 2. The base 1 is a metal base, and is in the shape of a shell with an open top. The bottom end face of the base 1 is an elliptical plane structure with a maximum diameter of 3 cm. An annular groove 12 is integrally formed on the side wall of the edge of the base 1. The silicon capsule 2 is a silicone top cover structure with a bulge in the middle, and an annular protrusion 21 that matches the annular groove 12 is integrally formed on the bottom edge of the silicon capsule 2; the annular protrusion 21 on the edge of the silicon capsule 2 is embedded in the annular groove 12 on the edge of the base 1 and the annular protrusion 21 is engaged and connected with the annular groove 12; the silicon capsule 2 is combined with the base 1 to form a sealed cavity 4 for containing liquid medicine; a catheter connector 11 is provided on one side of the base 1, which is connected to the inside of the sealed cavity 4 and is connected to the catheter device 3 through the catheter connector 11.

[0039] The catheter member 3 is a silicone catheter member, one end of which is provided with a positioning structure 31 and is threadedly connected to the catheter connector 11 through the positioning structure 31, and the other end of the catheter member 3 is inserted into the bladder tissue; the outer peripheral side wall of the end of the catheter member 3 inserted into the bladder tissue is provided with a plurality of side through holes 32 to increase the drug outlet area of ​​the catheter member 3; at the same time, the end of the catheter member 3 inserted into the bladder tissue is provided with a spiral bending structure to prevent the end of the catheter member 3 from detaching from the bladder tissue.

[0040] The entire bladder medication device is designed as a detachable structure, which is convenient for packaging, storage and transportation. At the same time, its assembly operation is convenient and quick, which further improves the use effect of the utility model.

[0041] Before use, the utility model firstly embeds the bladder drug delivery device in the subcutaneous tissue, and then inserts the catheter into the bladder tissue. Each time the bladder is instilled for chemotherapy, it is only necessary to use an ordinary syringe to inject the drug into the subcutaneous drug storage device through the skin and the silicon capsule, and the drug can enter the bladder through the catheter to achieve the purpose of bladder instillation chemotherapy; after the chemotherapy cycle is over, the bladder drug delivery device can be taken out from the subcutaneous tissue;

[0042] The utility model changes the administration method of bladder instillation chemotherapy, and no longer needs to insert the catheter frequently, and has the following beneficial effects:

[0043] 1. No need to administer the drug through the urethra, thus avoiding urethral injury, urinary tract infection and other conditions;

[0044] 2. It avoids the situation that the failure of catheter insertion affects the operation of chemotherapy, and is suitable for a wider range of people;

[0045] 3. Operators do not need professional training and can directly administer the drug subcutaneously. It is simple and convenient and can be completed by ordinary nursing staff;

[0046] 4. It avoids the pain caused by repeated insertion of the catheter, making the patient's bladder instillation chemotherapy more comfortable and easier to complete the chemotherapy cycle;

[0047] 5. The subcutaneous bladder drug delivery device only needs to be implanted once and can be used for a long time. It is low-cost and economical, which helps to reduce the financial burden of patients;

[0048] 6. The subcutaneous bladder drug delivery device is implanted superficially on the skin, making it easy to install and remove, and its safety performance is more reliable.

Claims

1. A subcutaneous implantable bladder drug delivery device, characterized in that: The subcutaneous implantable bladder drug delivery device includes a drug storage component and a catheter component, both of which are implanted in the subcutaneous tissue, the interior of the drug storage component is connected to one end of the catheter component, and the other end of the catheter component extends into the bladder tissue; the drug storage component includes a base and a silicon capsule, the base is arranged in the shape of a shell with an open top, the silicon capsule is a silicone top cover structure with a raised middle part, the bottom edge of the silicon capsule is sealed and connected to the edge of the base and combined with the base to form a sealed cavity for accommodating liquid medicine; a catheter connector connected to the interior of the sealed cavity is arranged on one side of the base and is connected to the catheter component through the catheter connector.

2. The subcutaneous implantable bladder drug delivery device according to claim 1, characterized in that: An annular groove is integrally formed on the side wall of the base edge, and an annular protrusion adapted to the annular groove is integrally formed on the bottom edge of the silicone capsule; when the silicone capsule is connected to the base, the annular protrusion on the edge of the silicone capsule is embedded in the annular groove on the edge of the base and the annular protrusion is engaged and connected with the annular groove.

3. The subcutaneous implantable bladder drug delivery device according to claim 2, characterized in that: The bottom end surface of the base is a plane structure, and the bottom end surface of the base is circular, elliptical, or triangular, but not limited to circular, elliptical, or triangular.

4. The subcutaneous implantable bladder drug delivery device according to claim 3, characterized in that: The base is a metal base or a biological material base.

5. The subcutaneous implantable bladder drug delivery device according to claim 4, characterized in that: The maximum diameter of the base is less than 5 cm.

6. The subcutaneous implantable bladder drug delivery device according to claim 5, characterized in that: One end of the catheter is provided with a positioning structure and is detachably connected to the catheter joint via the positioning structure, and the other end of the catheter is inserted into the bladder tissue.

7. The subcutaneous implantable bladder drug delivery device according to claim 6, characterized in that: The outer peripheral side wall of one end of the catheter inserted into the bladder tissue is provided with a plurality of side through holes to increase the medicine outlet area of ​​the catheter.

8. The subcutaneous implantable bladder drug delivery device according to claim 7, characterized in that: The end of the catheter inserted into the bladder tissue is arranged in a curved structure to prevent the end of the catheter from being separated from the bladder tissue.

9. The subcutaneous implantable bladder drug delivery device according to claim 8, characterized in that: The catheter member is a silicone catheter member.

Images